BR9712900A - Enzima liberadora de receptor de fator de necrose de tumor isolado, composições que compreendem a enzima e métodos de utilização da mesma - Google Patents

Enzima liberadora de receptor de fator de necrose de tumor isolado, composições que compreendem a enzima e métodos de utilização da mesma

Info

Publication number
BR9712900A
BR9712900A BR9712900-3A BR9712900A BR9712900A BR 9712900 A BR9712900 A BR 9712900A BR 9712900 A BR9712900 A BR 9712900A BR 9712900 A BR9712900 A BR 9712900A
Authority
BR
Brazil
Prior art keywords
enzyme
tnf
trre
methods
compositions
Prior art date
Application number
BR9712900-3A
Other languages
English (en)
Inventor
Gale A Granger
Tetsuya Gatanaga
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9712900A publication Critical patent/BR9712900A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Abstract

Patente de Invenção: <B>"POLIPEPTìDEO, POLINUCLEOTìDEO, ANTICORPO, MéTODO E USOS"<D>. A presente invenção refere-se a métodos de regulação indireta da atividade do TNF através da regulação da atividade ou da concentração da enzima liberadora do receptor de TNF (TRRE). Preferivelmente, a atividade da TRRE é regulada de modo local ao sítio da condição a ser tratada. No caso de doenças associadas aos níveis elevados do TNF, tais como a artrite reumatóide, a TRRE é administrada ao sítio da inflamação em uma quantidade suficiente para diminuir os níveis locais do TNF. No caso de doenças, tais como o câncer, que se beneficiam de níveis aumentados do TNF, o nível da TRRE é diminuído no sítio da doença.
BR9712900-3A 1996-11-06 1997-11-05 Enzima liberadora de receptor de fator de necrose de tumor isolado, composições que compreendem a enzima e métodos de utilização da mesma BR9712900A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3076196P 1996-11-06 1996-11-06
PCT/US1997/019930 WO1998020140A1 (en) 1996-11-06 1997-11-05 Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof

Publications (1)

Publication Number Publication Date
BR9712900A true BR9712900A (pt) 2000-11-28

Family

ID=21855891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712900-3A BR9712900A (pt) 1996-11-06 1997-11-05 Enzima liberadora de receptor de fator de necrose de tumor isolado, composições que compreendem a enzima e métodos de utilização da mesma

Country Status (14)

Country Link
US (3) US6569664B1 (pt)
EP (1) EP0938548B1 (pt)
JP (1) JP2001508648A (pt)
KR (1) KR100533531B1 (pt)
AT (1) ATE403714T1 (pt)
AU (1) AU744873B2 (pt)
BR (1) BR9712900A (pt)
CA (1) CA2270898A1 (pt)
DE (1) DE69738887D1 (pt)
ID (1) ID22049A (pt)
IL (1) IL129787A0 (pt)
NO (1) NO992187L (pt)
NZ (1) NZ335864A (pt)
WO (1) WO1998020140A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE403714T1 (de) * 1996-11-06 2008-08-15 Univ California Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
KR20060126844A (ko) * 1998-04-07 2006-12-08 메디뮨 인코포레이티드 백신용 폐렴 구균의 콜린 결합성 단백질의 유도체
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
US7148061B2 (en) * 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
AU2001245371A1 (en) 2000-02-28 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
JP5271480B2 (ja) * 2003-04-30 2013-08-21 味の素株式会社 体温低下抑制剤
WO2005030241A2 (en) * 2003-09-23 2005-04-07 Meyer Pharmaceuticals, Llc Treating inflammation using a biological agent that causes cells to release cytokine receptors
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
CA2619663A1 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. Human ribosomal dna(rdna) and ribosomal rna (rrna) nucleic acids and uses thereof
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
TWI527603B (zh) * 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
CN102171541B (zh) 2009-01-06 2013-03-27 西门子医疗保健诊断公司 用于使用成像确定容器中的液面的方法和装置
PE20141436A1 (es) 2011-01-24 2014-11-15 Abbvie Biotechnology Ltd Dispositivos de inyeccion automatica con superficies de agarre sobremoldeadas

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5643740A (en) 1983-02-24 1997-07-01 Ronald J. Billing Monoclonal antibody specific for activated lymphocytes and monocytes
US5001061A (en) * 1983-06-22 1991-03-19 Lubrizol Genetics, Inc. nifD promoter of Bradyrhizobium
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
JPH0611709B2 (ja) 1984-10-19 1994-02-16 チロン コーポレイション 角膜基質創傷の治療のための組成物
JPH088870B2 (ja) 1985-02-05 1996-01-31 サイナ−ゲン バイオロジカルズ，インコ−ポレ−テツド メタロプロテイナ−ゼ阻害剤の配列をもつ組換ベクタ−系及びメタロプロテイナ−ゼ阻害剤製造のための組換ｄｎａ
US4695590A (en) 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US6869924B1 (en) 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
ATE219776T1 (de) 1989-03-21 2002-07-15 Us Secretary United States Dep Matrizenmetalloproteinase-inhibitor-peptide
US5140043A (en) 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5270326A (en) 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
JP3068879B2 (ja) 1991-03-09 2000-07-24 フマキラー株式会社 精製ダニアレルゲン
EP0534907B1 (en) 1991-09-26 1998-08-05 Nippon Zoki Pharmaceutical Co., Ltd. The use of furanone derivatives for the prevention or treatment of autoimmune diseases
AU675413B2 (en) 1991-09-30 1997-02-06 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Recombinant immunotoxins
EP0563485A1 (en) 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
WO1994022309A1 (en) 1993-04-07 1994-10-13 Glycomed Incorporated Synthetic matrix metalloprotease inhibitors and uses thereof
WO1995009913A1 (en) 1993-10-07 1995-04-13 Incyte Pharmaceuticals, Inc. Human monocyte/macrophage derived metalloproteinase inhibitor
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
JP3758187B2 (ja) * 1994-01-28 2006-03-22 味の素株式会社 マガキ由来のトランスグルタミナーゼ
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
ZA955430B (en) 1994-07-07 1997-02-13 Res Dev Foundation Tumor necrosis factor receptor-ii associated protein kinase and method for their use
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6090605A (en) 1996-03-11 2000-07-18 The Board Of Trustees Of The University Of Arkansas Purified porcine kidney L-fucose kinase
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
US5834236A (en) 1996-06-27 1998-11-10 The Salk Institute For Biological Studies AATT repeat transcription enhancer element
US5853977A (en) * 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
ATE403714T1 (de) * 1996-11-06 2008-08-15 Univ California Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen
US6030785A (en) 1997-03-05 2000-02-29 University Of Washington Screening methods to identify agents that selectively inhibit hepatitis C virus replication
US6183997B1 (en) 1997-03-21 2001-02-06 Stratagene Polymerase enhancing factor (PEF) extracts PEF protein complexes isolated PEF proteins and methods for purifying and identifying same

Also Published As

Publication number Publication date
KR20000053073A (ko) 2000-08-25
EP0938548B1 (en) 2008-08-06
ATE403714T1 (de) 2008-08-15
CA2270898A1 (en) 1998-05-14
NO992187L (no) 1999-07-01
DE69738887D1 (de) 2008-09-18
KR100533531B1 (ko) 2005-12-06
WO1998020140A1 (en) 1998-05-14
AU744873B2 (en) 2002-03-07
EP0938548A1 (en) 1999-09-01
NO992187D0 (no) 1999-05-05
NZ335864A (en) 2001-09-28
ID22049A (id) 1999-08-26
US6573062B1 (en) 2003-06-03
IL129787A0 (en) 2000-02-29
US6569664B1 (en) 2003-05-27
US6858402B2 (en) 2005-02-22
US20030170776A1 (en) 2003-09-11
JP2001508648A (ja) 2001-07-03
AU5162198A (en) 1998-05-29

Similar Documents

Publication Publication Date Title
BR9712900A (pt) Enzima liberadora de receptor de fator de necrose de tumor isolado, composições que compreendem a enzima e métodos de utilização da mesma
Argilés et al. Cancer cachexia: the molecular mechanisms
Pufe et al. The angiogenic peptide vascular endothelial growth factor is expressed in foetal and ruptured tendons
Hattori et al. Tumor necrosis factor stimulates the synthesis and secretion of biologically active nerve growth factor in non-neuronal cells.
Starksen et al. Regulated expression of the platelet-derived growth factor A chain gene in microvascular endothelial cells.
Bessis et al. The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis
Sandle Salt and water absorption in the human colon: a modern appraisal
Cazaubon et al. Endothelin induces tyrosine phosphorylation and GRB2 association of Shc in astrocytes.
Redlich et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis
Jacobsen et al. Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling
Naveilhan et al. 1, 25-Dihydroxyvitamin D3 regulates the expression of the low-affinity neurotrophin receptor
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
HUT76875A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
Armbrecht et al. Expression of 25-hydroxyvitamin D 24-hydroxylase cytochrome P450 in kidney and intestine Effect of 1, 25-dihydroxyvitamin D and age
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
Petersen et al. The splice variants 120 and 164 of the angiogenic peptide vascular endothelial cell growth factor (VEGF) are expressed during Achilles tendon healing
Layé et al. Effects of lipopolysaccharide and glucocorticoids on expression of interleukin-1β converting enzyme in the pituitary and brain of mice
Bicknell 60 YEARS OF POMC: N-terminal POMC peptides and adrenal growth
Feldmann et al. The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards?
BR0012408A (pt) Métodos para induzir ou aumentar a migração celular, para reduzir ou inibir a migração celular, para induzir ou aumentar a cura de ferimento em um paciente, e para regular a expressão de pelo menos um gene de uma célula, e, uso de um agonista de fator de tecido
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
GEP19991604B (en) Human Follicle Stimulating Hormone Receptor
Khavinson et al. Effect of epitalon on interleukin-1beta signal transduction and the reaction of thymocyte blast transformation under stress
Korneva et al. The role of interleukin-1 in stress-induced changes in immune system function
Birt et al. Corticosterone supplementation reduced selective protein kinase C isoform expression in the epidermis of adrenalectomized mice

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: A REQUERENTE APRESENTOU NOVO QUADRO REIVINDICATORIO CONTENDO 47 (QUARENTA E SETE) REIVINDICACOES. NO ENTANTO, NAO HOUVE O PAGAMENTO DA TAXA CORRESPONDENTE AO VALOR DAS REIVINDICACOES EXCEDENTES. A REQUERENTE DEVERA COMPLEMENTAR O VALOR DA TAXA DE EXAME REFERENTE AS REIVINDICACOES EXCEDENTES, PARA QUE SE DE PROSSEGUIMENTO AO EXAME TECNICO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.